PDF) Statins, Fibrates and Myopathy: Pathophysiological Mechanism, Risk Factors and Laboratory Markers

Statins, Fibrates and Myopathy: Pathophysiological Mechanism, Risk Factors and Laboratory Markers

Investigating Lipid-Modulating Agents for Prevention or Treatment of COVID-19: JACC State-of-the-Art Review

Efficacy and Safety of Pitavastatin in a Real-World Setting: Observational Study Evaluating SaFety in Patient Treated with Pitavastatin in Korea (PROOF Study)

JCM, Free Full-Text

Myopathy with statin-fibrate combination therapy: clinical considerations - Document - Gale OneFile: Health and Medicine

Frontiers Cardiovascular Abnormalities in Juvenile Dermatomyositis: A Scoping Review for the Clinical Rheumatologists

Regulatory Effects and Molecular Mechanisms of Tea and Its Active Compounds on Nonalcoholic Fatty Liver Disease

Considerations in the Approach to Appropriate Statin Selection

Improving Cardiovascular Risk Assessment to Optimize Therapy

Statins, fibrates, thiazolidinediones and resveratrol as adjunctive therapies in sepsis: could mitochondria be a common target?, Intensive Care Medicine Experimental

Cholesterol Lowering Drugs - Endotext - NCBI Bookshelf

Frontiers Autoantibodies in the pathogenesis of idiopathic inflammatory myopathies: Does the endoplasmic reticulum stress response have a role?

Bile Acid Sequestrants for Hypercholesterolemia Treatment Using Sustainable Biopolymers: Recent Advances and Future Perspectives

triglyc-drugs-Image001.jpg

Hypertriglyceridemia: Practice Essentials, Pathophysiology, Etiology

IJMS, Free Full-Text